ArticleFrontiers in microbiology2026
Cell-free DNA metagenomic next generation sequencing for the diagnosis of infectious diseases: a retrospective assessment of clinical utility in a tertiary and quaternary care facility.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We sought to retrospectively assess the clinical utility of a commercially available plasma cell-free DNA (cfDNA) metagenomic next generation sequencing (mNGS) known as the Karius test (KT), for the diagnosis of infectious diseases, stratified by clinical syndrome. Methods: Retrospective chart review and abstraction were performed to assess the clinical impact of KT. Descriptive statistics were used to characterize the results of the KT in conjunction with host parameters. Results: This study included 120 KT results from 114 patients, collected from September 1, 2021, through August 31 Conclusion: Taken together, these data suggest that despite the relatively high rate of organism detection by KT, clinical impact is modest. Based on effect size analyses, this study identified several clinical scenarios that warrant larger scale prospective investigation to more completely elucidate high-yield use cases of KT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.